Focus: RoslinCT is a UK-based stem cell biotechnology company focused on cell therapy development, operating as a public entity since 2006. The company specializes in translating stem cell science into therapeutic applications.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Stable — net -3 jobs in 30d
10 added, 13 removed. Backfill posture.
RoslinCT represents a science-driven stem cell platform play with long-term potential, but lack of clinical progress and opaque financial health make it a higher-risk choice versus better-capitalized peers.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for RoslinCT
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from RoslinCT's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles